Evidence map›Paper›PMID 41255572›Full record

ReviewResearch (Washington, D.C.)2025

Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer.

Feiran Zhang, Ziyi Zhou, Peng Zhang, Shao Li

Abstract readReview
In one paragraph

Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Special Issue "Molecular Biomarkers in Cancers: Advances and Challenges".International journal of molecular sciences · 2026
    Article
  2. The Dynamic Alliance of p53 and Metabolism in the Tumor Microenvironment Shapes Tumor Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Feiran ZhangInstitute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China.
Ziyi ZhouInstitute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China.
Peng ZhangInstitute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China.
Shao LiInstitute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China.ORCID https://orcid.org/0000-0002-8709-9167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comprehensive understanding of premalignant lesions (PMLs) represents a pivotal opportunity for cancer early detection and interception. Recently, advances in multi-omics technologies and artificial intelligence (AI) methods have provided unprecedented insights into PML-induced tumorigenesis. In this paper, we firstly catalog clinically recognized PMLs across 15 cancer types, emphasizing their epidemiological profiles and malignant transformation potentials. Then, we summarize recent intriguing discoveries and remaining challenges from bulk, single-cell, and spatial omics studies, highlighting how these omics technologies reveal the dynamic molecular, cellular, and spatial evolution from precancerous states to invasive malignancies. We further discuss network-based computational strategies for multi-omics integration and tumorigenesis trajectory inference, with applications of recent deep learning-based AI approaches. Finally, we highlight translational implications for PMLs, including developing high-precision early-diagnosis biomarkers and targeted pharmacological preventive strategies. Collectively, this paper underscores how the convergence of high-resolution multi-omics with sophisticated AI is poised to redefine PML research, enabling pan-cancer exceedingly-early risk stratification and pharmacological prevention.

Identifiers

PMID41255572
PMCPMC12620627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.